Stocks
Traws Pharma, Inc.TRAW
NASDAQHealthcareBiotechnology$0.22
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing oral small-molecule antivirals for respiratory infections, including COVID-19 and influenza. Its lead candidates target viral polymerases and proteases, with early-stage data that investors monitor for potential differentiation from existing therapies. The company also holds a preclinical oncology pipeline, though antiviral programs drive current valuation.
52W Range: $0.22-$3.23
Congressional Interest in Traws Pharma, Inc. (TRAW)
No congressional trades have been disclosed for Traws Pharma, Inc. (TRAW) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading TRAW?
No congressional trades found for this stock.